Current treatment status-Not currently treated - Page 24 of 28 Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

Is active surveillance an option for African American men with low-risk prostate cancer?

Is active surveillance an option for African American men with low-risk prostate cancer?

Posted by on Aug 15, 2013 in Prostate cancer | 0 comments

In a nutshell This study examined the possible role of active surveillance (AS) as a treatment strategy for African American (AA) men whose prostate cancer is considered to be of low-risk. Some background Prostate cancer is a condition in which cells of the prostate gland grow and divide uncontrollably. In some cases, this uncontrolled growth...

Read More

The addition of ganitumab or conatumumab to chemotherapy in the treatment of metastatic colorectal cancer

Posted by on Jul 19, 2013 in Colorectal cancer | 0 comments

In a nutshell This study compared the ability of two drugs, ganitumab and conatumumab, to treat patients with metastatic colorectal cancer when added to chemotherapy. Some background Cancer cells express various structures on their surface (called receptors) that may stimulate growth and help avoid destruction by the immune system. Drugs that...

Read More

The effect of cetuximab with chemotherapy in patients with unresectable liver metastases

Posted by on Jul 17, 2013 in Colorectal cancer | 0 comments

In a nutshell This study explored whether cetuximab (erbitux) can benefit patients with unresectable colorectal liver metastases. The ability to perform surgery to remove part or all of the tumor growth in the liver (the resection rate) was compared between patients receiving cetuximab in combination with chemotherapy, to those receiving chemotherapy...

Read More

The effect of cabazitaxel and prednisone in the treatment of metastatic castration resistant prostate cancer

Posted by on Jul 16, 2013 in Prostate cancer | 0 comments

In a nutshell This study looked at the effect, and specifically drug related toxicities, of cabazitaxel (jevtana) plus prednisone treatment in metastatic prostate cancer patients. Some background Prostate cancer grows in response to the hormone testosterone. In order to reduce the effect of testosterone, castration is the mainstay of advanced...

Read More

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Posted by on Jun 29, 2013 in Breast cancer | 0 comments

In a nutshell This study tested the effect of complete axillary lymph node removal, on survival without recurrence of the cancer (called disease free survival or DFS) in patients with breast cancer.  Some background Lymph nodes are small organs which are part of the immune system. They filter fluid called lymph. Lymph can be thought of as the...

Read More

The outcome of salvage prostate cryotherapy is related to PSA levels before treatment

The outcome of salvage prostate cryotherapy is related to PSA levels before treatment

Posted by on May 19, 2013 in Prostate cancer | 0 comments

In a nutshell The study presented here investigated the predictive value of pre-treatment Prostate Serum Antigen (PSA) levels in patients with recurrent localized prostate cancer as a prognostic marker for successful salvage prostate cryotherapy. The authors found that a PSA level of < 5 ng/ml is a prognostic marker for a successful treatment...

Read More

Is frequent PSA testing associated with increased recurrence detection and survival in patients treated for prostate cancer?

Is frequent PSA testing associated with increased recurrence detection and survival in patients treated for prostate cancer?

Posted by on May 11, 2013 in Prostate cancer | 0 comments

In a nutshell The present study evaluated whether more frequent prostate-specific antigen (PSA) monitoring in patients treated for prostate cancer (PCa) was associated with earlier detection of cancer recurrence (return of the cancer) or survival. The number of PSA screenings had no effect on patient survival after treatment for PCa. Some...

Read More

The association between lifestyle and cardiovascular disease in colorectal cancer survivors

Posted by on May 8, 2013 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to assess how many colorectal cancer (CRC) survivors had a cardiovascular disease (CVD) and to determine the association between lifestyle factors and CVD. In this study overweight CRC survivors were more likely to suffer from CVD. Some background In the last years the number of CRC survivors has increased...

Read More

Eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers

Eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers

Posted by on Apr 19, 2013 in Colorectal cancer | 0 comments

In a nutshell This phase III trial aims to determine the benefits of using the drugs eflornithine and sulindac (Clinoril) in the prevention of high risk adenomas and secondary colorectal cancers. Researchers will look at the number of recurrences over a 3 year period while administering the drugs. The details Patients previously treated for...

Read More

Predicting residual or recurrent disease in patients with invasive colorectal adenocarcinoma developed from colorectal adenoma treated by endoscopy?

Predicting residual or recurrent disease in patients with invasive colorectal adenocarcinoma developed from colorectal adenoma treated by endoscopy?

Posted by on Apr 10, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated factors associated with residual or recurrent disease in patients with colorectal adenocarcinomas developed from adenomas initially treated endoscopically. Some background A colorectal adenoma is a benign (non-cancerous) abnormal growth in the inner lining of the large intestine (colon and rectum) also...

Read More